Voloridge Investment Management
AMLX icon

Voloridge Investment Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Voloridge Investment Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-153,363
Closed -$1.85M – 988
2025
Q4 		$1.85M Buy
+153,363
New +$2.08M 0.01% 928
2024
Q1 		– Sell
-465,445
Closed -$6.85M – 1135
2023
Q4 		$6.85M Buy
465,445
+196,478
+73% +$3.01M 0.03% 551
2023
Q3 		$4.92M Buy
268,967
+154,338
+135% +$3.26M 0.02% 665
2023
Q2 		$2.47M Sell
114,629
-20,836
-15% -$563K 0.01% 926
2023
Q1 		$3.97M Sell
135,465
-159,802
-54% -$5.55M 0.02% 753
2022
Q4 		$10.9M Sell
295,267
-86,945
-23% -$3.09M 0.06% 407
2022
Q3 		$10.8M Buy
+382,212
New +$9.54M 0.06% 421

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Voloridge Investment Management's AMLX Position: Q1 2026 in Review

Voloridge Investment Management sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2026, closing a stake of 153,363 shares — an estimated $1.85M sold.

Voloridge Investment Management first reported a position in AMLX in Q3 2022 and held it in 7 quarters. The position peaked at $10.9M in Q4 2022. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Voloridge Investment Management reported no remaining Amylyx Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Voloridge Investment Management sold 153,363 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $1.85M.
  • Voloridge Investment Management first reported a position in Amylyx Pharmaceuticals in Q3 2022 and held it in 7 quarters.
  • Voloridge Investment Management's Amylyx Pharmaceuticals position peaked at $10.9M in Q4 2022.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Voloridge Investment Management's 13F filing for Q1 2026, filed 15 May 2026.